摘要
目的评价重组人血管内皮抑素（恩度）联合FOLFOX4方案治疗晚期大肠癌的有效性和安全性。方法经病理组织学检查确诊的晚期大肠癌患者18例接受恩度联合FOLFOX4方案治疗。恩度15mg加生理盐水500ml静脉缓慢滴注，d1-d14间歇7天，重复给药；FOLFOX4方案具体为：奥沙利铂（L—OHP）85mg／m^2，静脉滴人2h，d1；亚叶酸钙（CF）200mg／m^2，静脉滴入2h，氟尿嘧啶（5-FU）400mg／m^2静脉推注后予以600mg／m^2持续静脉滴入22h，d．～d2。每2周重复，28天为1周期；3～4周期后评价疗效。结果18例患者均如期完成治疗，可评价客观疗效和安全性。获PR 11例，SD3例，PD4例，客观有效率为61．1％（11／18），疾病控制率为77．8％（14／18）。主要毒副反应为骨髓抑制、消化道反应和周围神经毒性，无4级毒副反应，无心律失常及出血发生。结论恩度联合FOLFOX4方案治疗晚期大肠癌具有协同作用，疗效好，毒性低，安全性好，值得临床进一步观察。
Objective To evaluate the validity and drug safety of endostar and FOLFOX 4 regimen in advanced colorectal carcinoma. Methods Eighteen advanced colorectal carcinoma patients by pathological were observed. They were treated with endostar and FOLFOX 4 regimen, Endostar（ 15mg solved in 500ml of normal saline） was slowly dropped from day 1 to 14, repeating after a week. FOLFOX 4 regimen： oxaliplatin 85mg/m^2 iv infusion for 2 hours, d1 ;CF 200mg/m^2 iv infusion for 2 hours followed by 5-FU 400mg/m^2 iv bolus and 600mg/m^2 iv infusion for 22 hours, dl-d2. Every two weeks was repeated. 28 days was a cycle. Patients were evaluated after 3-4 cycles. Results Among 18 cases, there were 11 cases PR, 3 cases SD and 4 cases PD. The response rate was 61, 1% （11/18） and the disease control rate was 77.8% （14/18）. The main adverse effects were bone marrow suppression, gastrointestinal toxicity and neurotoxicity. There was no toxicity and adverse effect of grade 4 in these patients. Arrhythmia and hemorrhage did not occur. Conclusion Endostar and FOLFOX 4 regimen in advanced colorectal carcinoma have advantages including good therapeutic effects and less adverse reaction for the patients and it worth further study.
出处
《临床肿瘤学杂志》
CAS
2010年第7期655-657,共3页
Chinese Clinical Oncology
